Cargando…

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis

INTRODUCTION: Alterations in expression and activity of human receptor tyrosine kinases (RTKs) are associated with cancer progression and in response to therapeutic intervention. METHODS: Thus, protein abundance of 21 RTKs was assessed in 15 healthy and 18 cancerous liver samples [2 primary and 16 c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vasilogianni, Areti-Maria, Al-Majdoub, Zubida M., Achour, Brahim, Peters, Sheila Annie, Rostami-Hodjegan, Amin, Barber, Jill
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986493/ https://www.ncbi.nlm.nih.gov/pubmed/36890818 http://dx.doi.org/10.3389/fonc.2023.1010563

Ejemplares similares

Quantitative Proteomics of Hepatic Drug‐Metabolizing Enzymes and Transporters in Patients With Colorectal Cancer Metastasis
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2022)

Proteomics of colorectal cancer liver metastasis: A quantitative focus on drug elimination and pharmacodynamics effects
por: Vasilogianni, Areti‐Maria, et al.
Publicado: (2021)

Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

Non-uniformity of Changes in Drug-Metabolizing Enzymes and Transporters in Liver Cirrhosis: Implications for Drug Dosage Adjustment
por: El-Khateeb, Eman, et al.
Publicado: (2021)

Liquid Biopsy Enables Quantification of the Abundance and Interindividual Variability of Hepatic Enzymes and Transporters
por: Achour, Brahim, et al.
Publicado: (2020)

Mass spectrometry‐based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin
por: Al‐Majdoub, Zubida M., et al.
Publicado: (2020)

Quantitative Proteomics of Clinically Relevant Drug-Metabolizing Enzymes and Drug Transporters and Their Intercorrelations in the Human Small Intestine
por: Couto, Narciso, et al.
Publicado: (2020)

Liquid Biopsy for Patient Characterization in Cardiovascular Disease: Verification against Markers of Cytochrome P450 and P‐Glycoprotein Activities
por: Achour, Brahim, et al.
Publicado: (2022)

In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition
por: Murata, Yukiko, et al.
Publicado: (2022)

Altered Bioavailability and Pharmacokinetics in Crohn’s Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs
por: Alrubia, Sarah, et al.
Publicado: (2022)

Inhibition of aggregation of amyloid-β through covalent modification with benzylpenicillin; potential relevance to Alzheimer's disease
por: Alsalahat, Izzeddin, et al.
Publicado: (2021)

Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With Confidence
por: Rostami‐Hodjegan, Amin
Publicado: (2017)

Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?
por: Frechen, Sebastian, et al.
Publicado: (2022)

Opening a debate on open‐source modeling tools: Pouring fuel on fire versus extinguishing the flare of a healthy debate
por: Rostami‐Hodjegan, Amin, et al.
Publicado: (2021)

Precision medicine technology hype or reality? The example of computer-guided dosing
por: Polasek, Thomas M., et al.
Publicado: (2019)

Editorial: Precision Medicine: Impact of Cytochromes P450 and Transporters Genetic Polymorphisms, Drug-Drug Interactions, Disease on Safety and Efficacy of Drugs
por: Daali, Youssef, et al.
Publicado: (2022)

Novel minimal physiologically-based model for the prediction of passive tubular reabsorption and renal excretion clearance
por: Scotcher, Daniel, et al.
Publicado: (2016)

Assessing Potential Drug–Drug Interactions Between Dabigatran Etexilate and a P‐Glycoprotein Inhibitor in Renal Impairment Populations Using Physiologically Based Pharmacokinetic Modeling
por: Doki, Kosuke, et al.
Publicado: (2019)

Application of the Nested Enzyme‐Within‐Enterocyte (NEWE) Turnover Model for Predicting the Time Course of Pharmacodynamic Effects
por: Takita, Hiroyuki, et al.
Publicado: (2020)

Proof of Concept in Assignment of Within-Subject Variability During Virtual Bioequivalence Studies: Propagation of Intra-Subject Variation in Gastrointestinal Physiology Using Physiologically Based Pharmacokinetic Modeling
por: Bego, Margareta, et al.
Publicado: (2022)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

Proteome-wide dataset supporting functional study of tyrosine kinases in breast cancer
por: Angelopoulos, Nicos, et al.
Publicado: (2016)

Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations
por: Scotcher, Daniel, et al.
Publicado: (2017)

Precision dosing to avoid adverse drug reactions
por: Polasek, Thomas M., et al.
Publicado: (2019)

Seeing what is behind the smokescreen: A systematic review of methodological aspects of smoking interaction studies over the last three decades and implications for future clinical trials
por: Hermann, Robert, et al.
Publicado: (2023)

Targeted mass-spectrometry-based assays enable multiplex quantification of receptor tyrosine kinase, MAP kinase, and AKT signaling
por: Whiteaker, Jeffrey R., et al.
Publicado: (2021)

Quantification and localization of oncogenic receptor tyrosine kinase variant transcripts using molecular inversion probes
por: van den Heuvel, Corina N. A. M., et al.
Publicado: (2018)

Protein tyrosine kinase 6 is associated with nasopharyngeal carcinoma poor prognosis and metastasis
por: Liu, Li-na, et al.
Publicado: (2013)

Deconvolution and IVIVC: Exploring the Role of Rate-Limiting Conditions
por: Margolskee, Alison, et al.
Publicado: (2015)

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling Within a Bayesian Framework to Identify Poor Metabolizers of Efavirenz (PM), Using a Test Dose of Efavirenz
por: Chetty, Manoranjenni, et al.
Publicado: (2018)

Effect of Chronic Kidney Disease on the Renal Secretion via Organic Anion Transporters 1/3: Implications for Physiologically‐Based Pharmacokinetic Modeling and Dose Adjustment
por: Tan, Shawn Pei Feng, et al.
Publicado: (2022)

Quantifying gut wall metabolism: methodology matters
por: Hatley, Oliver J.D., et al.
Publicado: (2017)

Optimization of intestinal microsomal preparation in the rat: A systematic approach to assess the influence of various methodologies on metabolic activity and scaling factors
por: Hatley, Oliver J.D., et al.
Publicado: (2017)

Considerations and Caveats when Applying Global Sensitivity Analysis Methods to Physiologically Based Pharmacokinetic Models
por: Liu, Dan, et al.
Publicado: (2020)

Tyrosine Kinases in Cancer
por: Blau, Olga, et al.
Publicado: (2015)

Role of Bruton's tyrosine kinase (BTK) in growth and metastasis of INA6 myeloma cells
por: Bam, R, et al.
Publicado: (2014)

Tyrosine kinase LYN is an oncotarget in human cervical cancer: A quantitative proteomic based study
por: Liu, Shuaibin, et al.
Publicado: (2016)

Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases
por: Stern, David F
Publicado: (2000)

Targeting Spleen Tyrosine Kinase-Bruton's Tyrosine Kinase Axis for Immunologically Mediated Glomerulonephritis
por: Chen, Jin-Shuen, et al.
Publicado: (2014)

Pyk2 is a Novel Tau Tyrosine Kinase that is Regulated by the Tyrosine Kinase Fyn
por: Li, Chuanzhou, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_o7sjrdth32g4jmb8sus4tlhm0h